On March 7, Community Health Systems (CHS), based in Franklin, Tennessee, became the inaugural hospital system to form a partnership with and procure medications from Mark Cuban Cost Plus Drug Co., marking a significant step in addressing drug supply challenges and the escalating costs of pharmaceuticals. This collaboration aims to tackle issues such as pharmaceutical waste, drug shortages, and enhancing patient safety and medication error prevention by leveraging flexible drug ordering options, including offering medications in alternative vial sizes to minimize waste and dosage errors. Furthermore, Cost Plus Drugs is set to commence the production of epinephrine and norepinephrine in its new $11 million drug manufacturing facility in Dallas, with plans to extend its manufacturing to injectable drugs in shortage and pediatric oncology solutions. This partnership aligns with Cost Plus Drugs' ongoing efforts to integrate into the health system industry, offering a marketplace for essential medicines to hospitals, ASCs, clinics, and other healthcare facilities.

Mark Cuban's drug company partners with 1st health system Becker's Hospital Review

Salesforce introduced AI tools for healthcare: Einstein Copilot and Assessment Generation to ease administrative tasks and combat physician burnout. These tools automate appointment setting, patient data summarization, and digital health assessments, integrating medical data from various sources. Aimed at reducing clerical burden, these solutions are part of Salesforce's broader strategy to streamline healthcare data management, with availability set for summer and year-end.

Salesforce announces new AI tools for doctors CNBC

UnitedHealth aims to fully restore Change Healthcare post-ransomware by mid-March, impacting U.S. healthcare operations since a February cyberattack. Systems like electronic prescribing have resumed, with full payment services expected by March 15. UnitedHealth, undeterred by further system threats, introduces financial aid for affected healthcare providers, with the program expanding to meet broader needs without immediate repayment. Change Healthcare identified Blackcat ransomware as the attack source, posing significant risks to patient safety and data security.

UnitedHealth working to restore Change Healthcare systems by mid-March, company says CNBC

GE HealthCare, in collaboration with Vanderbilt University Medical Center (VUMC), has developed artificial intelligence (AI) models capable of predicting cancer patients' responses to immunotherapies with 70% to 80% accuracy by analyzing diverse sets of data from over 2,200 patients. These models utilize electronic medical records, including demographic, genomic, tumor, cellular, proteomic, and imaging data, to forecast both efficacy outcomes and the likelihood of severe side effects such as hepatitis, colitis, and pneumonitis. This advancement aims to move beyond the current trial-and-error methodologies and reliance on novel biomarkers, providing a more precise, data-driven approach to cancer treatment. GE HealthCare is exploring the commercialization of these AI technologies to enhance patient care and support biopharma drug development, contingent on regulatory approvals.

GE HealthCare, Vanderbilt AI models predict immunotherapy responses among cancer patients FierceBiotech

On March 7, Community Health Systems (CHS), based in Franklin, Tennessee, became the inaugural hospital system to form a partnership with and procure medications from Mark Cuban Cost Plus Drug Co., marking a significant step in addressing drug supply challenges and the escalating costs of pharmaceuticals. This collaboration aims to tackle issues such as pharmaceutical waste, drug shortages, and enhancing patient safety and medication error prevention by leveraging flexible drug ordering options, including offering medications in alternative vial sizes to minimize waste and dosage errors. Furthermore, Cost Plus Drugs is set to commence the production of epinephrine and norepinephrine in its new $11 million drug manufacturing facility in Dallas, with plans to extend its manufacturing to injectable drugs in shortage and pediatric oncology solutions. This partnership aligns with Cost Plus Drugs' ongoing efforts to integrate into the health system industry, offering a marketplace for essential medicines to hospitals, ASCs, clinics, and other healthcare facilities.

Mark Cuban's drug company partners with 1st health system Becker's Hospital Review

Salesforce introduced AI tools for healthcare: Einstein Copilot and Assessment Generation to ease administrative tasks and combat physician burnout. These tools automate appointment setting, patient data summarization, and digital health assessments, integrating medical data from various sources. Aimed at reducing clerical burden, these solutions are part of Salesforce's broader strategy to streamline healthcare data management, with availability set for summer and year-end.

Salesforce announces new AI tools for doctors CNBC

UnitedHealth aims to fully restore Change Healthcare post-ransomware by mid-March, impacting U.S. healthcare operations since a February cyberattack. Systems like electronic prescribing have resumed, with full payment services expected by March 15. UnitedHealth, undeterred by further system threats, introduces financial aid for affected healthcare providers, with the program expanding to meet broader needs without immediate repayment. Change Healthcare identified Blackcat ransomware as the attack source, posing significant risks to patient safety and data security.

UnitedHealth working to restore Change Healthcare systems by mid-March, company says CNBC

GE HealthCare, in collaboration with Vanderbilt University Medical Center (VUMC), has developed artificial intelligence (AI) models capable of predicting cancer patients' responses to immunotherapies with 70% to 80% accuracy by analyzing diverse sets of data from over 2,200 patients. These models utilize electronic medical records, including demographic, genomic, tumor, cellular, proteomic, and imaging data, to forecast both efficacy outcomes and the likelihood of severe side effects such as hepatitis, colitis, and pneumonitis. This advancement aims to move beyond the current trial-and-error methodologies and reliance on novel biomarkers, providing a more precise, data-driven approach to cancer treatment. GE HealthCare is exploring the commercialization of these AI technologies to enhance patient care and support biopharma drug development, contingent on regulatory approvals.

GE HealthCare, Vanderbilt AI models predict immunotherapy responses among cancer patients FierceBiotech